E García-Giralt
- Oncology top 5%
- Cancer Research top 5%
- Molecular Biology
- Immunology
- Pathology and Forensic Medicine top 10%
- Topics
- Cancer Treatment and Pharmacology (15 papers)Immunotherapy and Immune Responses (9 papers)Cancer Immunotherapy and Biomarkers (9 papers)
- Cited by
- Cancer ResearchOncologyDermatology
- Partner nations
- FranceUnited StatesNetherlands
In The Last Decade
E García-Giralt
62 papers receiving 873 citations
Peers
Comparison fields: 5 of 74
- Oncology 577
- Cancer Research 332
- Molecular Biology 195
- Immunology 147
- Pathology and Forensic Medicine 129
Countries citing papers authored by E García-Giralt
This map shows the geographic impact of E García-Giralt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E García-Giralt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E García-Giralt more than expected).
Fields of papers citing papers by E García-Giralt
This network shows the impact of papers produced by E García-Giralt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E García-Giralt. The network helps show where E García-Giralt may publish in the future.
Co-authorship network of co-authors of E García-Giralt
This figure shows the co-authorship network connecting the top 25 collaborators of E García-Giralt. A scholar is included among the top collaborators of E García-Giralt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E García-Giralt. E García-Giralt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 11 | |
| 3 | 5 | |
| 4 | 9 | |
| 5 | 12 | |
| 6 | [The role of metastron in the treatment of prostate cancer]. | 0 |
| 7 | 6 | |
| 8 | 5 | |
| 9 | 14 | |
| 10 | 133 | |
| 11 | 70 | |
| 12 | 281 | |
| 13 | [Malignant epidermoid degeneration of dermoid cysts of the ovary. Apropos of 2 cases]. | 5 |
| 14 | [Metastatic breast cancer. Chemotherapy with adriamycin, vindesine, cyclophosphamide and 5 FU. Value of continuous 5 FU perfusion. Results of controlled trials]. | 4 |
| 15 | [Encephalopathy caused by an ifosfamide-mesna combination]. | 1 |
| 16 | [Hepatic metastases of breast cancer. Analysis of the parameters which influence the response to chemotherapy]. | 6 |
| 17 | 6 | |
| 18 | Inhibition of graft-versus-host-reaction (GVHR) by in vitro incubation of donor lymphocytes with thymic or splenic chalone (s). | 6 |
| 19 | Extraction of an inhibitor of DNA synthesis from human peripheral blood lymphocytes and bovine spleen. | 33 |
| 20 | 16 |
About E García-Giralt
E García-Giralt is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 63 papers that have together received 943 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (15 papers), Immunotherapy and Immune Responses (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). The work is most often cited by research in Cancer Research (332 citations), Oncology (577 citations) and Dermatology (77 citations). E García-Giralt has collaborated with scholars based in France, United States and Netherlands. Frequent co-authors include P Pouillart, T Palangié, M Jouve, Thierry Dorval, Pierre Kerbrat, M. Namer, R Keiling, Alain Monnier, F.M. Delgado and P. Fumoleau. Their work appears in journals such as Nature, Science and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.